Vasoactive Intestinal Peptide (VIP) - Induced pulmonary vasodilation mediated by EDRF/NO in isolated perfused rat lungs

S. Iwabuchi, S. Ono, J. Funata, Y. Hoshikawa, S. Ueda, Y. Ashino, T. Tanita, S. Fujimura, K. Koike

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We studied the effects of Vasoactive Intestinal Peptide (VIP) on the pulmonary circulation in isolated perfused rat lungs. VIP caused pulmonary vasodilation in a dose-dependent manner. This effect was inhibited by pretreatment with L-Nω nitro-arginine (L-NNA), a competitive inhibitor of endothelium-derived relaxing factor (EDRF/NO), but not by meclofenamate, a cyclooxygenase inhibitor. Addition of L-arginine, a substrate of EDRF/NO, after treatment with L-NNA reversed VIP-induced pulmonary vasodilation. These results indicate that VIP causes pulmonary vasodilation, and they suggest a role for EDRF/NO in VIP-induced pulmonary vasodilation in isolated rat lungs.

Original languageEnglish
Pages (from-to)262-267
Number of pages6
JournalJapanese Journal of Thoracic Diseases
Volume33
Issue number3
Publication statusPublished - 01-01-1995
Externally publishedYes

Fingerprint

Vasoactive Intestinal Peptide
Vasodilation
Lung
Arginine
Meclofenamic Acid
Endothelium-Dependent Relaxing Factors
Pulmonary Circulation
Cyclooxygenase Inhibitors

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Iwabuchi, S. ; Ono, S. ; Funata, J. ; Hoshikawa, Y. ; Ueda, S. ; Ashino, Y. ; Tanita, T. ; Fujimura, S. ; Koike, K. / Vasoactive Intestinal Peptide (VIP) - Induced pulmonary vasodilation mediated by EDRF/NO in isolated perfused rat lungs. In: Japanese Journal of Thoracic Diseases. 1995 ; Vol. 33, No. 3. pp. 262-267.
@article{5dce4419ab0c4dddb06f5e6cc8958a42,
title = "Vasoactive Intestinal Peptide (VIP) - Induced pulmonary vasodilation mediated by EDRF/NO in isolated perfused rat lungs",
abstract = "We studied the effects of Vasoactive Intestinal Peptide (VIP) on the pulmonary circulation in isolated perfused rat lungs. VIP caused pulmonary vasodilation in a dose-dependent manner. This effect was inhibited by pretreatment with L-Nω nitro-arginine (L-NNA), a competitive inhibitor of endothelium-derived relaxing factor (EDRF/NO), but not by meclofenamate, a cyclooxygenase inhibitor. Addition of L-arginine, a substrate of EDRF/NO, after treatment with L-NNA reversed VIP-induced pulmonary vasodilation. These results indicate that VIP causes pulmonary vasodilation, and they suggest a role for EDRF/NO in VIP-induced pulmonary vasodilation in isolated rat lungs.",
author = "S. Iwabuchi and S. Ono and J. Funata and Y. Hoshikawa and S. Ueda and Y. Ashino and T. Tanita and S. Fujimura and K. Koike",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "33",
pages = "262--267",
journal = "Respiratory Investigation",
issn = "2212-5345",
publisher = "Elsevier BV",
number = "3",

}

Iwabuchi, S, Ono, S, Funata, J, Hoshikawa, Y, Ueda, S, Ashino, Y, Tanita, T, Fujimura, S & Koike, K 1995, 'Vasoactive Intestinal Peptide (VIP) - Induced pulmonary vasodilation mediated by EDRF/NO in isolated perfused rat lungs', Japanese Journal of Thoracic Diseases, vol. 33, no. 3, pp. 262-267.

Vasoactive Intestinal Peptide (VIP) - Induced pulmonary vasodilation mediated by EDRF/NO in isolated perfused rat lungs. / Iwabuchi, S.; Ono, S.; Funata, J.; Hoshikawa, Y.; Ueda, S.; Ashino, Y.; Tanita, T.; Fujimura, S.; Koike, K.

In: Japanese Journal of Thoracic Diseases, Vol. 33, No. 3, 01.01.1995, p. 262-267.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Vasoactive Intestinal Peptide (VIP) - Induced pulmonary vasodilation mediated by EDRF/NO in isolated perfused rat lungs

AU - Iwabuchi, S.

AU - Ono, S.

AU - Funata, J.

AU - Hoshikawa, Y.

AU - Ueda, S.

AU - Ashino, Y.

AU - Tanita, T.

AU - Fujimura, S.

AU - Koike, K.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - We studied the effects of Vasoactive Intestinal Peptide (VIP) on the pulmonary circulation in isolated perfused rat lungs. VIP caused pulmonary vasodilation in a dose-dependent manner. This effect was inhibited by pretreatment with L-Nω nitro-arginine (L-NNA), a competitive inhibitor of endothelium-derived relaxing factor (EDRF/NO), but not by meclofenamate, a cyclooxygenase inhibitor. Addition of L-arginine, a substrate of EDRF/NO, after treatment with L-NNA reversed VIP-induced pulmonary vasodilation. These results indicate that VIP causes pulmonary vasodilation, and they suggest a role for EDRF/NO in VIP-induced pulmonary vasodilation in isolated rat lungs.

AB - We studied the effects of Vasoactive Intestinal Peptide (VIP) on the pulmonary circulation in isolated perfused rat lungs. VIP caused pulmonary vasodilation in a dose-dependent manner. This effect was inhibited by pretreatment with L-Nω nitro-arginine (L-NNA), a competitive inhibitor of endothelium-derived relaxing factor (EDRF/NO), but not by meclofenamate, a cyclooxygenase inhibitor. Addition of L-arginine, a substrate of EDRF/NO, after treatment with L-NNA reversed VIP-induced pulmonary vasodilation. These results indicate that VIP causes pulmonary vasodilation, and they suggest a role for EDRF/NO in VIP-induced pulmonary vasodilation in isolated rat lungs.

UR - http://www.scopus.com/inward/record.url?scp=0029024244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029024244&partnerID=8YFLogxK

M3 - Article

C2 - 7739167

AN - SCOPUS:0029024244

VL - 33

SP - 262

EP - 267

JO - Respiratory Investigation

JF - Respiratory Investigation

SN - 2212-5345

IS - 3

ER -